LivaNova (NASDAQ:LIVN) Given Buy Rating at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of LivaNova (NASDAQ:LIVN) in a report issued on Friday morning, Benzinga reports. The brokerage currently has a $62.00 price target on the stock.

Several other analysts also recently issued reports on LIVN. Barclays upped their price objective on shares of LivaNova from $51.00 to $57.00 and gave the stock an equal weight rating in a report on Thursday, July 27th. StockNews.com initiated coverage on shares of LivaNova in a research report on Thursday, October 5th. They set a buy rating for the company. Mizuho lifted their price target on shares of LivaNova from $53.00 to $60.00 in a research report on Thursday, July 27th. Robert W. Baird lifted their price target on shares of LivaNova from $56.00 to $62.00 in a research report on Thursday, July 27th. Finally, HSBC started coverage on shares of LivaNova in a research report on Wednesday, September 6th. They set a hold rating and a $52.00 price target for the company. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of Hold and a consensus target price of $59.33.

LivaNova Stock Up 0.2 %

NASDAQ LIVN opened at $46.86 on Friday. LivaNova has a 12 month low of $40.26 and a 12 month high of $59.86. The company’s 50 day simple moving average is $50.71 and its 200 day simple moving average is $51.15. The company has a debt-to-equity ratio of 0.46, a current ratio of 3.23 and a quick ratio of 2.68. The company has a market capitalization of $2.52 billion, a P/E ratio of 937.20 and a beta of 0.89.

LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, November 1st. The company reported $0.73 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.09. LivaNova had a net margin of 0.27% and a return on equity of 12.10%. The firm had revenue of $286.10 million for the quarter, compared to the consensus estimate of $271.97 million. During the same period in the previous year, the firm posted $0.58 earnings per share. The firm’s revenue was up 13.3% on a year-over-year basis. Equities research analysts expect that LivaNova will post 2.26 earnings per share for the current fiscal year.

Institutional Trading of LivaNova

A number of institutional investors have recently made changes to their positions in the business. Bank of Montreal Can increased its holdings in LivaNova by 213.3% during the first quarter. Bank of Montreal Can now owns 35,725 shares of the company’s stock worth $2,912,000 after buying an additional 24,324 shares during the last quarter. Panagora Asset Management Inc. bought a new position in LivaNova in the 1st quarter valued at approximately $256,000. Rhumbline Advisers increased its position in LivaNova by 2.1% during the 1st quarter. Rhumbline Advisers now owns 147,621 shares of the company’s stock valued at $12,080,000 after purchasing an additional 2,980 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in shares of LivaNova by 10.5% during the 1st quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 19,506 shares of the company’s stock worth $1,596,000 after buying an additional 1,859 shares during the period. Finally, Yousif Capital Management LLC grew its position in shares of LivaNova by 2.4% during the 1st quarter. Yousif Capital Management LLC now owns 28,279 shares of the company’s stock worth $2,314,000 after buying an additional 661 shares during the period. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.